What is thalassemia syndrome?

What is Thalassemia Syndrome

Thalassemia syndrome is a group of inherited hemoglobinopathies caused by genetic defects that result in reduced or absent synthesis of globin chains (alpha or beta), leading to ineffective erythropoiesis, chronic hemolytic anemia, and iron overload. 1

Pathophysiology

The fundamental defect in thalassemia involves:

• Impaired globin chain production due to mutations in the HBA1/HBA2 genes (alpha thalassemia) or HBB gene (beta thalassemia), typically inherited in an autosomal recessive pattern 2
• Globin chain imbalance resulting in accumulation of unpaired chains that precipitate and damage developing erythroblasts and mature red blood cells 3
• Ineffective erythropoiesis with destruction of red cell precursors in the bone marrow combined with hemolytic anemia from peripheral red cell destruction 4, 3
• Progressive iron overload from both increased gastrointestinal absorption (due to hepcidin suppression) and transfusional iron accumulation (approximately 200 mg per unit of blood) 1

Geographic Distribution and Epidemiology

• Beta thalassemia major originated in Mediterranean, Middle Eastern, and Asian regions where malaria was endemic 1
• Alpha thalassemia is also prevalent in malaria-endemic areas 5
• Both conditions now occur globally due to migration patterns and represent growing health problems in previously unaffected countries 1

Clinical Spectrum

Beta Thalassemia Major (Transfusion-Dependent)

• Life-threatening anemia beginning at approximately 1-2 years of age requiring lifelong blood transfusions 1
• Characterized by requiring >8 transfusion events per year in adults over 16 years 1
• Without treatment, causes hemolytic anemia, poor growth, and skeletal abnormalities during infancy 6

Beta Thalassemia Intermedia

• Less severe than major form with variable transfusion requirements 1
• Greater propensity for pulmonary hypertension and thrombosis compared to transfusion-dependent forms 1
• May require episodic rather than regular transfusions 6

Alpha Thalassemia Variants

• Silent carriers and trait carriers are asymptomatic and require no treatment 6
• Hemoglobin H disease (alpha thalassemia intermedia) causes hemolytic anemia 6
• Hemoglobin Bart's (alpha thalassemia major) usually results in fatal hydrops fetalis 6

Major Complications and Mortality

Cardiac Disease

• Heart disease is the predominant cause of death in beta thalassemia major, accounting for approximately 70% of deaths in the deferoxamine chelation era 1
• Iron overload as the source of heart disease is the leading cause of death in transfusion-dependent patients 1
• Before chelation therapy, typical age at death was 10 years, primarily from cardiac causes; with deferoxamine, median age at death improved to 35 years by 2000 in the United Kingdom 1

Other Organ Damage

• Liver disease with rapid acceleration of fibrosis when iron amplifies toxic effects 1
• Endocrine dysfunction including hypothyroidism, diabetes, hypogonadism, and hypoparathyroidism 1, 7
• Growth and pubertal delays particularly in transfusion-dependent forms 7

Management Principles

Transfusion Strategy

• Target pre-transfusion hemoglobin of 9-10 g/dL with post-transfusion levels of 13-14 g/dL to suppress ineffective erythropoiesis while minimizing iron loading 1

Iron Chelation

• Lifelong iron chelation therapy is required to prevent or reverse iron-related complications in transfusion-dependent patients 1
• Essential for preventing cardiac iron overload and extending survival 1

Curative Options

• Hematopoietic stem cell transplantation remains the only curative option, with current worldwide experience showing >90% patient survival and approximately 80% disease-free survival 1
• Gene therapy represents an emerging curative approach 4

Prognosis

• Silent carriers and trait carriers have normal life expectancy 6
• Transfusion-dependent patients historically died from cardiac complications of iron overload by age 30, though modern management has significantly improved outcomes 6
• Survival is strongly dependent on access to regular transfusions, effective chelation therapy, and birth cohort reflecting advances in care 1